Skip to content
Screener

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Amgen logo
AmgenAMGN
$1.95B+349%
WHW
Whitehawk TherapeuticsWHWK
-$2.78M-101%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$25.31M+286%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$45.12M+507%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$51M-191%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs(9)25,009
Proceeds from exercise of common stock options1,1901,134
Net cash provided by financing activities1,18126,143
Net increase in cash, cash equivalents and restricted cash44,96345,618
Cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, at beginning of period113,84085,183
Cash, cash equivalents and restricted cash, at end of period$158,803$130,801
Reconciliation of cash, cash equivalents and restricted cash

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s net change in cash?
IDEAYA Biosciences, Inc. (IDYA) reported net change in cash of $44.96M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s net change in cash changed year-over-year?
IDEAYA Biosciences, Inc.'s net change in cash decreased by 1.4% year-over-year, from $45.62M to $44.96M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s net change in cash?
Over 2 years (2022 to 2024), IDEAYA Biosciences, Inc.'s net change in cash has grown at a 76.1% compound annual growth rate (CAGR), from -$23.41M to -$72.59M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about IDEAYA Biosciences, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude